Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Cardiotonic Agents Market Forecast: What Value Will The Market Reach By 2030?#_x000D_
The cardiotonic agents market size has seen considerable expansion over recent years. Forecasts indicate an increase from $3.11 billion in 2025 to $3.5 billion in 2026, with a compound annual growth rate (CAGR) of 12.3%. The market’s past growth is attributable to factors such as the growing prevalence of heart failure, the need for inotropic support in critical care, the scarcity of alternative solutions for improving acute cardiac output, the proliferation of cardiac surgery procedures, and the hospital-focused approach to cardiovascular treatment._x000D_
_x000D_
The cardiotonic agents market is anticipated to show significant expansion in the coming years. It is projected to achieve a size of $5.56 billion in 2030, driven by a compound annual growth rate (CAGR) of 12.3%. This expected growth throughout the forecast period can be attributed to an aging global population, a rise in advanced heart failure cases, the demand for rapid-acting cardiac drugs, the expansion of critical care infrastructure, and improved monitoring within cardiac intensive care settings. Noteworthy trends during this same period involve the ongoing utilization of cardiotonic drugs for acute heart failure, a preference for their intravenous administration in hospitals, sustained demand for digitalis glycosides in treating arrhythmia, the integration of cardiotonic agents into surgical cardiac care, and a gradual shift towards combination cardiovascular therapy approaches._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Cardiotonic Agents Market Demand Drivers Opening New Revenue Streams#_x000D_
An increasing incidence of cardiovascular ailments is projected to boost the expansion of the cardiotonic agents market moving ahead. These diseases, often abbreviated as CVDs, encompass various conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, irregular heartbeats, and strokes. This surge in CVDs is largely attributed to poor dietary habits, specifically those rich in saturated and trans fats, salt, and added sugars, which in turn lead to obesity, hypertension, and heightened cholesterol. Cardiotonic agents work by enhancing the heart muscle’s efficiency and contractile power, facilitating improved blood flow and alleviating symptoms associated with numerous cardiovascular conditions. To illustrate, the World Health Organization, an intergovernmental entity based in Switzerland, reported 17.9 million fatalities from cardiovascular diseases in September 2023. Consequently, the increasing occurrence of cardiovascular diseases is fueling the expansion of the cardiotonic agents market._x000D_
_x000D_
#Cardiotonic Agents Market Breakdown By Product Type And Application#_x000D_
The cardiotonic agents market covered in this report is segmented – _x000D_
_x000D_
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types_x000D_
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations_x000D_
3) By Dosage Form: Tablet, Solution, Other Dosage Forms_x000D_
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications_x000D_
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C_x000D_
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone_x000D_
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine_x000D_
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine_x000D_
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol_x000D_
_x000D_
#Cardiotonic Agents Market Trends Powering Strategic Industry Growth#_x000D_
Leading firms within the cardiotonic agents market are concentrating on creating novel products, including short-term inotropic medications, to boost cardiac function in cases of acute heart failure and cardiogenic shock. These short-term inotropic drugs serve as treatments to temporarily strengthen the heart’s contractile power, consequently increasing cardiac output. An example is the launch of Dobutamine Injection, USP, in a 250 mg/20 mL vial by Hikma Pharmaceuticals plc, a UK pharmaceutical firm, in June 2023. This particular injection provides short-term inotropic support for adults suffering from cardiac decompensation stemming from diminished heart contractility, frequently resulting from heart disease or post-cardiac surgery. Its mechanism involves stimulating beta-1 receptors, which in turn boosts heart muscle contractility and cardiac output, exhibiting a swift onset of action (1–2 minutes). Administered intravenously, the injection is usually given in a hospital environment under strict monitoring._x000D_
_x000D_
#Cardiotonic Agents Market Company Landscape And Competitive Strategy#_x000D_
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd. _x000D_
_x000D_
#View The Full Cardiotonic Agents Market Report:#_x000D_
_x000D_
#Cardiotonic Agents Market Geographic Landscape: Which Region Leads Industry Growth?#_x000D_
North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model